New Jersey-based Legend Biotech Corp., a biotechnology company focused on life-threatening diseases, recently announced it will be opening a research and development (R&D) facility in Philadelphia.
The 31,000-square-foot facility will help the company advance its portfolio of next-generation cell therapies and expand its existing R&D footprint in the United States.
“This new facility underscores Legend’s commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation,” Dr. Ying Huang, Legend Biotech CEO, said. “We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partnerships with local, leading research institutions. We look forward to bolstering our cell therapy capabilities at this new site.”
The Philadelphia facility is expected to be completed during the third quarter of 2025 and will employ 55 people full time.
Legend Biotech develops advanced cell therapies across a diverse array of technology platforms including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy.
The company employs more than 1,200 people in the United States, and its three R&D facilities employ more than 350 people worldwide.